Antibody Drug Conjugate Market Proliferate Saliently at a CAGR of 19% till 2027 by Improving Technology-ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others

Antibody Drug Conjugate Market comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers.

Market Research Future (MRFR) has estimated in its latest report that the global antibody drug conjugate market is set to proliferate saliently at a CAGR of 19% during the forecast period 2017 to 2023.

The success of this technology has become possible only with increasing technological advancements. The potential of a cytotoxic drug embedded in the antibody drug conjugate is increased by 100–1000 fold more than the potential of cytotoxic drug when it acts alone.

Avail Sample copy for this Report at: https://www.marketresearchfuture.com/sample_request/1113

Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).

Industry Developments:

In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.

Market Segmentation:

By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.

By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.

By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.

By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.

The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers. The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.

Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.

Brows Full Detailed Research Report at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113

Intended Audience

Antibody drug conjugate manufacturing companies
Suppliers and distributors of antibody drug conjugate
Healthcare service providers
Health insurance players
Research and consulting firms
Medical research institutes
Venture capitalists
Community centers
Inquire for Discount at https://www.marketresearchfuture.com/check-discount/1113

Regional Analysis:

By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.